Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
NKGen Biotech, Inc. incurred loan of $343,000 with AlpineBrook Capital GP I Limited.
- Instrument
- loan
- Principal
- $343,000
- Counterparty
- AlpineBrook Capital GP I Limited
- Event
- incurrence
Exact text from the filing
The Alpine Fourth Amendment provides an additional $343,000 of funding to the Borrowers (the "Fifth Additional New Loan"). As a result, the principal amount of the Note was increased to $27,101,106.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NKGen Biotech, Inc. amended Alpine Fourth Amendment with AlpineBrook Capital GP I Limited valued at $343,000 (effective 2026-02-20).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- AlpineBrook Capital GP I Limited
- Value
- $343,000
- Effective
- 2026-02-20
Exact text from the filing
On February 20, 2026, NKGen Biotech, Inc. (the “Company”) and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “Borrowers”), entered into a fourth amendment (the “Alpine Fourth Amendment”) to that certain secured promissory note with AlpineBrook Capital GP I Limited, dated January 5, 2026, as amended by that certain amendment to secured promissory note dated January 12, 2026, that certain amendment no. 2 to secured promissory note dated January 23, 2026, and that certain amendment no. 3 to secured promissory note dated January 30, 2026 (the “Note”). The Alpine Fourth Amendment provides an additional $343,000 of funding to the Borrowers (the “Fifth Additional New Loan”).
View on SEC.gov